跳至主要内容
临床试验/NCT01331499
NCT01331499终止4 期

A Post-Market, Prospective, Multicenter, Randomized Trial Comparing the Use of Standard of Care Blood Sparing Techniques With and Without the Aquamantys System to Facilitate Hemostasis in Subjects Undergoing Multi-level Spinal Fusions

Salient Surgical Technologies6 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2011年4月1日最近更新:
适应症

试验速览

阶段
4 期
状态
终止
发起方
入组人数
12
试验地点
6
主要终点
Actual Peri-operative Blood Loss

研究概览

简要总结

The purpose of this study is to compare standard of care hemostasis techniques with and without the use of Aquamantys in reducing peri-operative blood loss.

详细描述

The primary objective of the study is to assess the effectiveness of Aquamantys in reducing peri-operative blood loss compared with standard electrocautery

Secondary objectives include :

  • Rate and volume of transfusions
  • Evaluating the reduction in hemoglobin and hematocrit values post- operatively
  • LOS costs, and operative time
  • Gathering operator feedback on qualitative criteria, including ease of use and surgical visualization between the two treatment groups

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Be candidate for three level (or greater) fusion surgery from T1 to S1 utilizing a direct posterior approach
  • Male or female 18 to 70 years of age (inclusive)
  • Must sign the IRB approved Informed Consent Form

排除标准

  • Undergoing spinal fusion for < 3 lumbar levels, or using an approach other than direct posterior
  • Undergoing an interbody fusion
  • Planned use of hypotensive anaesthesia
  • Pregnant or lactating
  • Morbid obesity, defined as Body Mass Index (BMI) greater than 40
  • Previously diagnosed coagulopathy or bleeding diasthesis
  • Currently, or within the previous 7 days prior to surgery, taking any medications that would produce bleeding diathesis including, but not limited to NSAIDs, aspirin, clopidogrel (Plavix), ticlopidine, or valproic acid
  • History of significant cardiac disorders that would necessitate special fluid management protocols
  • Serious trauma other than that confined to the spine
  • History of acute myocardial infarction and/or acute angina within the past year prior to enrollment
  • PT/INR >1.3 in the 14 days prior to surgery
  • PTT > 40 in the 14 days prior to surgery
  • Platelet count <100K in the 14 days prior to surgery
  • Based on clinical history, physical exam and subject presentation, subject has or is suspected to have a history of alcohol and/or drug abuse that would preclude subject from providing adequate consent and/or complying with study requirements
  • Prisoner or transient
  • Enrolled in another drug or device investigational study (currently or within past 30 days)
  • Unable or unwilling to sign the Informed Consent Form or comply with protocol specified procedures

结局指标

主要结局

Actual Peri-operative Blood Loss

时间窗: Up to 72 hours post-operatively

Actual blood loss (ABL) will be calculated using a study specified formula using laboratory data from up to 72 hours post-surgery. ABL will be compared between treatment groups

次要结局

  • Frequency and volume of transfusions(Up to 72 hours post-operatively)
  • Reduction in hemoglobin and hematocrit values post-operatively(Upto 72 hours post-operatively)
  • Length of stay costs and operativ time(Up to 21 days post-operatively)

研究者

发起方
Salient Surgical Technologies
申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验